Lizobakt tab. for resorption No. 30
Category
Sore throat
Scope of the drug
Dentistry
,
Ear, Throat, Nose
Release form
Tablet
Manufacturer country
Bosnia and Herzegovina
Package quantity, pcs
thirty
Dosage form
topical solution
Manufacturer
Infamed, Russia
Structure
Solution for topical application 0.01% colorless, transparent, foaming on shaking.
1 lbenzyldimethyl-myristoylamino-propylammonium chloride monohydrate 100 mg.
Excipients: purified water - up to 1 liter.
pharmachologic effect
Miramistin has a wide spectrum of antimicrobial activity, including hospital strains that are resistant to antibiotics.
The drug has a pronounced bactericidal effect against gram-positive (Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, etc.), gram-negative (Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., Etc.), aerobic and anaerobic bacteria, determined microbial associations, including hospital strains with multidrug resistance to antibiotics.
It has an antifungal effect on ascomycetes of the genus Aspergillus and genus Penicillium, yeast (Rhodotorula rubra, Torulopsis gabrata, etc.) and yeast-like fungi (Candida albicans, Candida tropicalis, Candida krusei, Pityrosporum orbiculare (Malassezia), furfurfurf dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton schoenleini, Trichophyton violacent, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis and other pathogenic fungi, etc.), and other pathogenic fungi , including fungal microflora with resistance to chemotherapy drugs.
It has an antiviral effect, is active against complex viruses (herpes viruses, human immunodeficiency virus, etc.).
Miramistin acts on the causative agents of sexually transmitted diseases (Chlamydia spp., Treponema spp., Trichomonas vaginalis, Neisseria gonorrhoeae, etc.).
Effectively prevents infection of wounds and burns.
It activates the regeneration processes.
Stimulates protective reactions at the site of application, by activating the absorption and digestion functions of phagocytes, potentiates the activity of the monocytic-macrophage system.
It has a pronounced hyperosmolar activity, as a result of which it relieves wound and perifocal inflammation, absorbs purulent exudate, contributing to the formation of a dry scab.
Does not damage granulation and viable skin cells, does not inhibit marginal epithelization.
Does not possess local irritating effect and allergenic properties.
Pharmacokinetics
When applied topically, miramistin does not have the ability to be absorbed through the skin and mucous membranes.
Indications
For use in surgery, traumatology:
prevention of suppuration and treatment of purulent wounds
- treatment of purulent-inflammatory processes of the musculoskeletal system.
For use in obstetrics, gynecology:
prevention and treatment of suppuration of postpartum injuries, perineal and vaginal wounds, postpartum infections
prevention and treatment of inflammatory diseases (vulvovaginitis, endometritis).
For use in combustiology:
treatment of superficial and deep burns of II and III A degree
preparation of burn wounds for dermatoplasty.
For use in dermatology, venereology:
treatment and prevention of pyoderma and dermatomycosis, candidiasis of the skin and mucous membranes,
individual prevention of sexually transmitted diseases (including syphilis, gonorrhea, chlamydia, trichomoniasis, genital herpes, genital candidiasis).
For use in urology:
complex treatment of acute and chronic urethritis and urethroprostatitis of a specific (, trichomoniasis, gonorrhea) and non-specific nature.
For use in dentistry:
treatment and prevention of infectious and inflammatory diseases of the oral cavity: stomatitis, gingivitis, periodontitis, periodontitis
hygienic processing of removable dentures.
For use in otorhinolaryngology:
complex treatment of acute and chronic sinusitis, tonsillitis, laryngitis
complex treatment of acute pharyngitis and / or exacerbation of chronic tonsillitis in children aged 3 to 14 years.
Contraindications
Individual intolerance to the drug.
Side effects
In some cases, a slight burning sensation may occur at the injection site, which disappears on its own after 15–20 s and does not require discontinuation of the drug.
Allergic reactions.
Interaction
With simultaneous use with antibiotics, an increase in their antibacterial and antifungal properties has been noted.
How to take, course of administration and dosage
Locally.
The drug is ready for use.
Instructions for using the spray pack:
1. Remove the cap from the bottle.
2. Remove the supplied spray nozzle from the protective packaging.
3. Attach the spray nozzle to the bottle.
4. Activate the spray nozzle by pressing again.
Surgery, traumatology, combustiology. For prophylactic and therapeutic purposes, the surface of wounds and burns is irrigated, wounds and fistulous passages are loosely tamponed, gauze tampons moistened with the drug are fixed. The treatment procedure is repeated 2-3 times a day for 3-5 days. A highly effective method of active drainage of wounds and cavities with a daily consumption of up to 1 liter of the drug.
Obstetrics, gynecology. In order to prevent postpartum infection, it is used in the form of vaginal irrigation before childbirth (5-7 days), during childbirth after each vaginal examination and in the postpartum period, 50 ml of the drug in the form of a tampon with an exposure of 2 hours for 5 days. When women are delivered by cesarean section, immediately before the operation, the vagina is treated, during the operation - the uterine cavity and an incision on it, and in the postoperative period, tampons moistened with the drug are inserted into the vagina with an exposure of 2 hours for 7 days. Treatment of inflammatory diseases is carried out in a course of 2 weeks by intravaginal administration of tampons with the drug, as well as by the method of drug electrophoresis.
Venereology.
For the prevention of sexually transmitted diseases, the drug is effective if it is used no later than 2 hours after intercourse.
Introduce the contents of the vial with the urological applicator into the urethra for 2-3 minutes: for men - 2-3 ml, for women - 1-2 ml, and into the vagina - 5-10 ml.
Treat the skin of the inner surfaces of the thighs, pubis, genitals.
After the procedure, it is recommended not to urinate for 2 hours.
Urology.
In the complex treatment of urethritis and urethroprostatitis, 2-3 ml of the drug is injected into the urethra 1-2 times a day, the course is 10 days.
Otorhinolaryngology.
With purulent sinusitis - during puncture, the maxillary sinus is washed with a sufficient amount of the drug.
Tonsillitis, pharyngitis and laryngitis are treated by gargling and / or irrigation using a spray nozzle, 3-4 times pressing 3-4 times a day.
The amount of the preparation for 1 rinse is 10-15 ml.
In children.
In case of acute pharyngitis and / or exacerbation of chronic tonsillitis, irrigation of the pharynx is carried out using a spray nozzle.
Children aged 3–6 years - 3-5 ml for one irrigation (single press on the head of the spray nozzle) 3-4 times a day
7-14 years old - 5-7 ml for one irrigation (double pressing) 3-4 times a day
over 14 years old - 10-15 ml per one irrigation (3-4 times pressing) 3-4 times a day.
The duration of therapy is from 4 to 10 days, depending on the timing of the onset of remission.
Dentistry.
For stomatitis, gingivitis, periodontitis, it is recommended to rinse the mouth with 10-15 ml of the drug 3-4 times a day.
Release form
topical solution
Storage conditions
At a temperature not exceeding 25 ° C.
Shelf life
3 years
Brand name
MIRAMISTIN
Active substance
Benzyldimethyl 3- (myristoylamino) propylammonium chloride monohydrate
Terms of dispensing from pharmacies
Without recipe
Name ENG
MIRAMISTIN
Clinical and pharmacological group
Topical antiseptic
ATX code
Quaternary ammonium compounds
Dosage
0.01% x 150ml
Structure
Solution for topical application 0.01% colorless, transparent, foaming on shaking. 1 lbenzyldimethyl-myristoylamino-propylammonium chloride monohydrate 100 mg.
Excipients: purified water - up to 1 liter.
Indications
Surgery, traumatology: prevention of suppuration and treatment of purulent wounds.
Treatment of purulent-inflammatory processes of the musculoskeletal system.
Obstetrics, gynecology: prevention and treatment of suppuration of postpartum injuries, perineal and vaginal wounds, postpartum infections, inflammatory diseases (vulvovaginitis, endometritis).
Combustiology: treatment of superficial and deep burns of II and IIIA degrees, preparation of burn wounds for dermatoplasty.
Dermatology, venereology: treatment and prevention of pyoderma and dermatomycosis, candidiasis of the skin and mucous membranes, mycoses of the feet.
Individual prevention of sexually transmitted diseases (including syphilis, gonorrhea, chlamydia, trichomoniasis, genital herpes, genital candidiasis).
Urology: complex treatment of acute and chronic urethritis and urethroprostatitis of a specific (chlamydia, trichomoniasis, gonorrhea) and non-specific nature.
Dentistry: treatment and prevention of infectious and inflammatory diseases of the oral cavity: stomatitis, gingivitis, periodontitis, periodontitis.
Hygienic treatment of removable dentures.
Otorhinolaryngology: complex treatment of acute and chronic otitis media, sinusitis, tonsillitis, laryngitis, pharyngitis.
In children aged 3 to 14 years, it is used for the complex treatment of acute pharyngitis and / or exacerbation of chronic tonsillitis.
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 3 years
Contraindications
Hypersensitivity to the drug.
INN / Active ingredient
Benzyldimethyl 3- (myristoylamino) propyl ammonium chloride monohydrate
Specifications
Scope of the drug
General
Release form
Solution
Manufacturer country
Russia
Package quantity, pcs
one
Way of introduction
Locally
Vacation conditions
Without recipe
Volume, ml.
150 ml
Brand name
Infamed
Components
spray nozzle
The amount of the dosage form in the primary package
150 ml
Primary packaging type
Bottle
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antiseptic
Anatomical and therapeutic characteristics
D08AJ Quaternary ammonium compounds
Dosage form
Topical solution
The target audience
Children
Expiration date in days
1095
Package weight, g
200
Category
:
Antiseptics and disinfectants
,
Antiviral
,
Regenerating agents
Mode of application
: https://translate.google.com/translate?hl=&sl=ru&tl=en&u=https://zz.buy-pharm.com/xzzajts.html;Description
Release form, composition and packaging
Lozenges, white or yellowish-white, round, with a dividing line on one side and bevels on both sides, inclusions in the form of dark spots are possible.
1 tab.
lysozyme hydrochloride
20 mg
pyridoxine hydrochloride
10 mg
lactose monohydrate - 155.4 mg, tragacanth gum - 10 mg, magnesium stearate - 4 mg, sodium saccharinate - 0.5 mg, vanillin - 0.1 mg.
10 pieces.
- blisters (1) - cardboard packs.
10 pieces.
- blisters (3) - cardboard packs.
pharmachologic effect
Antiseptic combined composition for topical use.
The effect of the drug is due to its constituent components.
Lysozyme is an enzyme of a protein nature, it is used as an antiseptic due to its direct effect on gram-positive and gram-negative bacteria, as well as fungi and viruses.
Takes part in the regulation of local nonspecific immunity.
Pyridoxine has a protective effect on the oral mucosa (has an antiphthous effect).
Does not affect the pharmacodynamic properties of lysozyme. ''
Indications for use
Treatment of infectious and inflammatory diseases of the oral mucosa, gums and larynx:
gingivitis
stomatitis
catarrhal phenomena of the upper respiratory tract
aphthous ulceration
herpetic lesions of the oral mucosa (as part of complex therapy)
erosion of the oral mucosa of various etiologies.
Contraindications for use
hereditary lactose intolerance, lactase deficiency or glucose / galactose malabsorption syndrome
children under 3 years old
hypersensitivity to drug components.
Dosage regimen
The drug is used topically in the oral cavity.
Children aged 3-7 years - 1 tab.
3 times a day, children aged 7-12 years - 1 tab.
4 times a day
adults and children over 12 years old are prescribed 2 tab.
3-4 times a day.
The course of treatment is 8 days.
Lizobact® tablets should be slowly dissolving without chewing, keeping the melted mass of the tablet in the mouth as long as possible, until complete dissolution.
Overdose
Overdose symptoms are unlikely, may occur after use in doses significantly higher than therapeutic and are manifested by a feeling of numbness, tingling sensation, as well as loss of sensitivity in the upper and lower extremities.
Treatment: drinking plenty of fluids (forced diuresis).
Side effect
Possibly: allergic reactions.
Drug interactions
When used together, Lizobact enhances the effect of antibiotics, incl.
penicillin, chloramphenicol, nitrofurantoin, enhances the effect of diuretics, weakens the activity of levodopa.
Isoniazid, penicillamine, pyrazinamide, immunosuppressants, estrogens and oral contraceptives may increase the need for pyridoxine (antagonistic effect against pyridoxine or increased renal excretion).
Application during pregnancy and lactation
It is possible to use the drug Lizobact during pregnancy and lactation (breastfeeding).
Special instructions In case of an allergic reaction, the use of the drug must be discontinued.
In such cases, the patient should consult a doctor.
Name ENG
LYSOBACT
Clinical and pharmacological group
Antiseptic for topical use in ENT practice and dentistry
ATX code
Other drugs
Dosage
20mg + 10mg
Structure
Active ingredients: lysozyme hydrochloride 20 mg
pyridoxine hydrochloride 10 mg Excipients: lactose monohydrate - 155.4 mg
gum tragacanth - 10 mg
magnesium stearate - 4 mg
sodium saccharinate - 0.5 mg
vanillin - 0.1 mg
Indications
Treatment of infectious and inflammatory diseases of the oral mucosa, gums and larynx: gingivitis stomatitis catarrhal phenomena of the upper respiratory tract aphthous ulceration herpetic lesions of the oral mucosa (as part of complex therapy) erosion of the oral mucosa of various etiologies.
INN / Active ingredient
Pyridoxine hydrochloride + lysozyme hydrochloride
Storage conditions and periods
At a temperature of 10-30 degrees.
Expiration date: 5 years
Contraindications
Contraindications to the use of hereditary lactose intolerance, lactase deficiency or glucose / galactose malabsorption syndrome children under 3 years of age hypersensitivity to drug components.
Specifications
Category
Sore throat
Scope of the drug
Dentistry
,
Ear, Throat, Nose
Release form
Tablet
Manufacturer country
Bosnia and Herzegovina
Package quantity, pcs
thirty
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Bosnalijek
The amount of the dosage form in the primary package
10 pieces.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antiseptic
Anatomical and therapeutic characteristics
R02AA20 Other antiseptics
Dosage form
Lozenges
Dosage (volume) of the substance in the preparation
lysozyme hydrochloride 20 mg
pyridoxine hydrochloride 10 mg
Expiration date in days
1825
The target audience
Children
Package weight, g
twenty
Mode of application
:
Topically. < br> The tablets should be slowly dissolved without chewing, keeping the melted mass of the tablet in the mouth as long as possible, until it is completely dissolved. < br> Children aged 3–7 years are usually prescribed 1 tablet 3 times a day, 7– 12 years old - 1 tablet 4 times a day.
Adults and children over the age of 12 - 2 tablets 3-4 times a day. < br> The course of treatment is 8 days.
Information on technical characteristics, delivery set, country of manufacture "